The effect of tolcapone on the pharmacokinetics of benserazide.
This study investigated the potential interaction between tolcapone, a catechol-O-methyltransferase (COMT) inhibitor, and the decarboxylase inhibitor, benserazide. In an open-labelled six-week study, patients with Parkinson's disease (PD), treated with levodopa/benserazide, were given tolcapone at 200 mg t.i.d. Blood samples for analysis of benserazide, its main active metabolite, trihydroxybenzylhydrazine, levodopa and 3-O- methyldopa (3-OMD) were collected immediately before and repeatedly after the first drug intake of the day at baseline and after 1-2 and 6 weeks of treatment. Furthermore, animal experiments were performed to determine the levels of benserazide and trihydroxybenzylhydrazine at doses for which safety had previously been established. It was shown that tolcapone can cause an increase in benserazide plasma concentrations and that this effect is dependent on the benserazide dose. When tolcapone was combined with 25 mg benserazide the elevation was small. Although the increase was more pronounced when tolcapone was combined with 50 mg benserazide, the levels were still substantially lower than concentrations causing toxicity in animals. The safety margin derived from this study, together with the absence of any organic toxic effects in clinical trials, show that the observed interaction between tolcapone and benserazide does not represent a safety concern for PD patients treated with this combination.
Jorga
K M
KM
Department of Research and Development, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
Larsen
J P
JP
Beiske
A
A
Schleimer
M
M
Fotteler
B
B
Schmitt
M
M
Moe
B
B
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D001545:Benserazide / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D001577:Benzophenones / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000493:pharmacokinetics; D007980:Levodopa / Q000008:administration & dosage / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors; D000077867:Tolcapone; D014443:Tyrosine / Q000031:analogs & derivatives / Q000493:pharmacokinetics
D000978:Antiparkinson Agents; D001577:Benzophenones; D004791:Enzyme Inhibitors; D006834:Hydrazines; D009596:Nitrophenols; C006307:2,3,4-trihydroxybenzylhydrazine; D014443:Tyrosine; D007980:Levodopa; D001545:Benserazide; D000077867:Tolcapone; C008404:3-methoxytyrosine